Plaque

Clinical Research Shows the Active Ingredient in Mikra’s Serenity Matches a Benzodiazepine in Effectiveness at Fighting Anxiety, Without Being Habit-Forming

Retrieved on: 
Wednesday, December 6, 2023

TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that European clinical research demonstrated that the active ingredient in Serenity, the newest product from its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”), is equally effective as a prescription-only benzodiazepine in treating the symptoms of anxiety.

Key Points: 
  • This research was particularly noteworthy because benzodiazepines, while widely prescribed for anxiety, carry substantial risk of dependency and of seizures in case of withdrawal2.
  • “It was this understanding that drove us to accelerate the launch of Serenity.
  • With Lifeist's expertise with fragrant and flavorful botanicals, Serenity is poised to become the best tasting lavender oil extract supplement on the market.
  • Plus, Serenity ships with a full 30-day supply in every bottle, as compared to the typical 7- or 14-day supply sold in competing lavender-based products.

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Retrieved on: 
Wednesday, December 6, 2023

The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

Key Points: 
  • The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including NLRP3 and AIM2) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in numerous diseases.
  • In the paper titled, “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” the authors studied mouse models of type 1 diabetes and atherosclerosis.
  • Results are consistent with other animal model studies showing deficiencies in essential inflammasome components, such as NLRP3, AIM2, ASC, and caspase-1, appear to protect against atherosclerosis.

Associa Hosts Annual SoCal Golf Tournament To Benefit Associa Cares

Retrieved on: 
Wednesday, November 29, 2023

Jaeschke , Professional Community Management, and The Prescott Companies are pleased to have hosted  their annual 2023 Southern California Associa Cares Golf Tournament fundraiser.

Key Points: 
  • Jaeschke , Professional Community Management, and The Prescott Companies are pleased to have hosted  their annual 2023 Southern California Associa Cares Golf Tournament fundraiser.
  • The event took place at Twin Oaks Golf Course and raised funds to benefit the company’s affiliate nonprofit, Associa Cares, which helps families and communities in need as a result of natural and man-made disasters.
  • More than 50 Associa team members, branch leaders, and vendor partners joined 30 sponsors at the event, including lead sponsor, CM2.
  • Following a relaxing day of golf, attendees had the opportunity to network with a wide range of Associa community managers and branch leaders.

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Retrieved on: 
Monday, November 27, 2023

As a result, there are currently no FDA approved stents for this specific indication.

Key Points: 
  • As a result, there are currently no FDA approved stents for this specific indication.
  • Retrospective analyses from large centers across the globe have suggested the safety and efficacy of stenting in conjunction with intracranial thrombectomy.
  • I am also excited that this brings the carotid disease as it pertains to neurointerventionalists to the forefront.
  • The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

Retrieved on: 
Monday, November 20, 2023

“Initiation of this milestone study of PMN310 marks our transition to a clinical stage company.

Key Points: 
  • “Initiation of this milestone study of PMN310 marks our transition to a clinical stage company.
  • We are excited to bring our precision medicine approach into the clinic in hopes of developing better therapeutics for neurodegenerative diseases,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • “Results from the Phase 1a study will facilitate dose selection for subsequent Phase 1b study in patients with Mild Cognitive Impairment (MCI) due to AD and patients with mild AD.
  • In addition, our Phase 1b study will provide important insights into the safety profile of PMN310, which we anticipate may differentiate PMN310 from other available and potentially disease-modifying treatments.”

Skout’s Honor Debuts NEW Oral Care Launch Video

Retrieved on: 
Thursday, November 16, 2023

OCEANSIDE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Skout’s Honor , the award-winning pet specialty brand loved for its life-changing pet essentials, today released a launch video , highlighting its all new Oral Care line - which is available for retailers to order now.

Key Points: 
  • OCEANSIDE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Skout’s Honor , the award-winning pet specialty brand loved for its life-changing pet essentials, today released a launch video , highlighting its all new Oral Care line - which is available for retailers to order now.
  • The launch video showcases Skout’s Honor’s eye-catching, modern, “brushless” oral care products that break down and fight plaque and tartar, while freshening breath - fast.
  • In addition to its latest Oral Care launch, Skout’s Honor is best known for its life-changing Probiotic Grooming and topical Wellness products, plant-based, powerful Stain and Odor products, Flea + Tick solutions and preventative Training Aids.
  • Go to skoutshonor.com/pages/oral-care to learn more about Skout’s Honor’s Oral Care, which is available and ready to ship - just in time for Pet Dental Month (February 2024).

Krach Institute for Tech Diplomacy at Purdue Names Winners of its 2023 Freedom Scholarship

Retrieved on: 
Thursday, December 7, 2023

Today, the Krach Institute for Tech Diplomacy at Purdue announced the winners of its 2023 Freedom Scholarship.

Key Points: 
  • Today, the Krach Institute for Tech Diplomacy at Purdue announced the winners of its 2023 Freedom Scholarship.
  • Keith Krach, chairman and co-founder of the Krach Institute for Tech Diplomacy at Purdue, commented, "The mission of the Krach Institute—ensuring that technology advances freedom—is a long-term endeavor that requires us to invest in the development of the next generation of Tech Diplomacy leaders.
  • 2023 Krach Institute Freedom Scholarship Winners:
    Caitlin Clark serves as the president of Kappa Delta Sorority Theta Nu Chapter and has served as the vice president of inclusion for the chapter.
  • Internships: The Krach Institute for Tech Diplomacy at Purdue's internship program is designed to create a talent pipeline, enabling students from Purdue and other universities to gain hands-on experience in Tech Diplomacy.

iHeartMedia Los Angeles’ KOST 103.5 and Children’s Hospital Los Angeles Launch Eighth Annual Season of Giving Fundraising Campaign on Tuesday, Nov. 28

Retrieved on: 
Tuesday, November 28, 2023

For the eighth consecutive year, iHeartMedia Los Angeles’ KOST 103.5 will join Children’s Hospital Los Angeles on Giving Tuesday, Nov. 28, to celebrate the global day of giving that takes place on the first Tuesday after Thanksgiving.

Key Points: 
  • For the eighth consecutive year, iHeartMedia Los Angeles’ KOST 103.5 will join Children’s Hospital Los Angeles on Giving Tuesday, Nov. 28, to celebrate the global day of giving that takes place on the first Tuesday after Thanksgiving.
  • Starting with the Ellen K Morning Show, KOST 103.5 will dedicate 13 hours of programming to CHLA on Giving Tuesday, from 5 a.m. to 6 p.m.
  • KOST listeners are invited to support the hospital by visiting kost1035.com/chla , or by dialing #250 from a mobile phone and using keyword “CHLA” to donate.
  • Children’s Hospital Los Angeles is one of the top pediatric academic medical and research institutions in the United States and relies on the generosity of community support.

Rapid Medical's TIGERTRIEVER™ Delivers First-Pass Success in Challenging Ischemic Stroke Patients with ICAD

Retrieved on: 
Thursday, November 16, 2023

Rapid Medical™, a leading developer of advanced neurovascular devices, announces new data demonstrating excellent first-pass treatment success with the TIGERTRIEVER™ device in complex ischemic stroke patients with underlying intracranial atherosclerotic disease (ICAD).

Key Points: 
  • Rapid Medical™, a leading developer of advanced neurovascular devices, announces new data demonstrating excellent first-pass treatment success with the TIGERTRIEVER™ device in complex ischemic stroke patients with underlying intracranial atherosclerotic disease (ICAD).
  • “Patients with ICAD experiencing a stroke are very challenging to treat and often need rescue therapy such as stenting,” states Dr. Edgar Samaniego , Endovascular Neurologist at the University of Iowa and lead author.
  • “We achieved very high treatment success and lasting results with TIGERTRIEVER alone that we haven’t seen with other devices.
  • Moreover, TIGERTRIEVER in ICAD rivals the results only thought possible in non-ICAD patients.

Care Access To Begin Enrolling Warwick Residents in Clinical Trial for Potential Heart Attack and Stroke Prevention Drug

Retrieved on: 
Wednesday, November 15, 2023

Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide.

Key Points: 
  • Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide.
  • “The impact of heart attack and stroke can impede members of our Warwick community from living longer, healthier lives,” said Dr. Sudhir Bansal, Principal Investigator for Care Access - Warwick.
  • The convenient setting provides residents of Warwick and surrounding communities the option to participate in clinical trials close to home.
  • To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com .